Sang Hun Song

Sang Hun Song

Auto-generated profile, based on publicly available information

Sang Hun Song

Department of Urology, Seoul National University Bundang Hospital, 300, Gumi-Dong, Bundang-Gu, Seongnam-Si, 463-707, Kyunggi-Do, Korea.

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Investigative and Clinical Urology
Verified
Journal Article
Open access
PDF file
SSSang Hun Song
Sang Hun Song
SBSeok-Soo Byun
Seok-Soo Byun
Song SH, et al. Investig Clin Urol. 2021 May;62(3):256-266. https://doi.org/10.4111/icu.20210124

28 October 2022 in Investigative and Clinical Urology
Verified
Journal Article
Open access
PDF file
CYChanghee Ye
Changhee Ye
JHJin-Nyoung Ho
Jin-Nyoung Ho
DKDan Hyo Kim
Dan Hyo Kim
SSSang Hun Song
Sang Hun Song
HKHwanik Kim
Hwanik Kim
SLSangchul Lee
Sangchul Lee
Ye C, et al. Investig Clin Urol. 2022 Nov;63(6):631-638. https://doi.org/10.4111/icu.20220056

30 August 2022 in Journal of the American Medical Informatics Association
Verified
Journal Article
Closed access
PDF file
SSSang Hun Song
Sang Hun Song
HKHwanik Kim
Hwanik Kim
JKJung Kwon Kim
Jung Kwon Kim
HLHakmin Lee
Hakmin Lee
JOJong Jin Oh
Jong Jin Oh
SBSeok-Soo Byun
Seok-Soo Byun
Objective: Despite efforts to improve screening and early detection of prostate cancer (PC), no available biomarker has shown acceptable performance in patients with prostate-specific antigen (PSA) gray zones. We aimed to develop a deep learning-based prediction model with minimized parameters and missing value handling algorithms for PC and clinically significant PC (CSPC). Materials and Methods: We retrospectively analyzed data from 18 824 prostate biopsies collected between March 2003 and December 2020 from 2 databases, resulting in 12 739 cases in the PSA gray zone of 2.0–10.0 ng/mL. Dense neural network (DNN) and extreme gradient boosting (XGBoost) models for PC and CSPC were developed with 5-fold cross-validation. The area under the curve of the receiver operating characteristic (AUROC) was compared with that of serum PSA, PSA density, free PSA (fPSA) portion, and prostate health index (PHI). Results: The AUROC values in the DNN model with the imputation of missing values were 0.739 and 0.708 (PC) and 0.769 and 0.742 (CSPC) in internal and external validation, whereas those of the non-imputed dataset were 0.740 and 0.771 (PC) and 0.807 and 0.771 (CSPC), respectively. The performance of the DNN model was like that of the XGBoost model, but better than all tested clinical biomarkers for both PC and CSPC. The developed DNN model outperformed PHI, serum PSA, and percent-fPSA with or without missing value imputation. Discussion: DNN models for missing value imputation can be used to predict PC and CSPC. Further validation in real-life scenarios are need to recommend for actual implementation, but the results from our study support the increasing role of deep learning analytics in the clinical setting. Conclusions: A deep learning model for PC and CSPC in PSA gray zones using minimal, routinely used clinical parameter variables and data imputation of missing values was successfully developed and validated.

1 January 2022 in Investigative and Clinical Urology
Verified
Journal Article
Open access
PDF file
SSSang Hun Song
Sang Hun Song
EKEunae Kim
Eunae Kim
EWEunjin Woo
Eunjin Woo
EKEunkyung Kwon
Eunkyung Kwon
SYSungroh Yoon
Sungroh Yoon
SBSeok-Soo Byun
Seok-Soo Byun
Song SH, et al. Investig Clin Urol. 2022 Jan;63(1):42-52. https://doi.org/10.4111/icu.20210305

27 March 2024 in Prostate International
Verified
Journal Article
Open access
JNJunhyun Nam
Junhyun Nam
JKJung Kwon Kim
Jung Kwon Kim
JOJong Jin Oh
Jong Jin Oh
SLSangchul Lee
Sangchul Lee
SBSeok-Soo Byun
Seok-Soo Byun
SSSang Hun Song
Sang Hun Song
To evaluate functional outcome after robot-assisted radical prostatectomy (RARP) and high-intensity focused ultrasound (HIFU) ablation for prostate cancer. We retrospectively reviewed 4,983 RARP and 230 HIFU procedures performed at a single tertiary center. A 1:4 ratio propensity score matching (PSM) was performed to achieve baseline equivalence in age, body mass index (BMI), comorbidities, clinical stage, prostate specific antigen (PSA), prostate volume, biopsy grade, and number of positive cores. Functional outcomes based on International Prostate Symptom Score (IPSS), International Index of Erectile Function (IIEF-5) scores, and incontinence rates were evaluated at 6, 12, and 24 months. total of 193 HIFU cases matched to 760 cases of RARP, were included. No differences were observed in perioperative IPSS at all follow-up periods. Despite comparative erectile function at baseline, HIFU showed significantly better erectile function preservation compared to RARP, with mean IIEF-5 scores of 9.5 versus 4.8, 9.5 versus 5.8, and 8.4 versus 6.7 at 6, 12, and 24 months, respectively (all P < 0.001). Pad-free rates at 6 and 12 months were comparable, with over 96% achieving continence at 12 months in both groups, although the rate of ≤1 pad/day at last follow-up was slightly better in HIFU (98.9% vs. 96.7%, P = 0.049). Subgroup analysis on partial (PGA) and whole gland ablation (WGA) showed no differences in IIEF-5 and incontinence but increased voiding difficulty in WGA versus PGA after 12 months of therapy (P < 0.05). Preoperative IIEF-5 ≥17 and HIFU were significant predictors of early erectile function recovery at 6 months (HR 4.4 and 5.0; all P < 0.001). No differences were observed in treatment-free survival between PGA, WGA, and RARP. HIFU shows better performance in early recovery and preservation of erectile function after treatment for prostate cancer without increasing the risk of treatment failure. Patients with moderate to severe erectile dysfunction (IIEF-5 <17) prior to surgery should be warned of poor recovery after treatment.

1 January 2023 in Investigative and Clinical Urology
Verified
Journal Article
Open access
PDF file
SSSang Hun Song
Sang Hun Song
SLSangchul Lee
Sangchul Lee
Song SH, et al. Investig Clin Urol. 2023 Sep;64(5):425-434. https://doi.org/10.4111/icu.20230187